Emiltatug Ledadotin

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameEmiltatug Ledadotin
Drug Alias NameEmi-LeXMT-1660
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > AF-HPA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionApoptosis stimulantsMitosis inhibitorsTubulin inhibitors +[5] 
TargetsTubulinV-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMersana Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMersana Therapeutics IncDay One Biopharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A